정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2284 | Active, not recruiting | A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive. | COVID-19 Infection | Drug: Camostat | Phase 2 | Cancer Research UK, Latus Therapeutics | OTHER | 100 | All | 18 Years | Chawton Park Surgery, Alton, United Kingdom The University of Edinburgh, Edinburgh, United Kingdom Church Avenue Medical Group, Harrogate, United Kingdom Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom Trafalgar Medical Practice, Portsmouth, United Kingdom Preston Lantern Centre, Preston, United Kingdom Clarence Medical Centre, Rhyl, United Kingdom Velindre Cancer Centre, Wales, United Kingdom Eynsham Medical Centre, Witney, United Kingdom |
2283 | Completed | A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19) | Covid19 | Drug: ATI-450 Drug: Placebo |
Phase 2 | University of Kansas Medical Center | OTHER | 20 | All | 18 Years | The University of Kansas Medical Center, Kansas City, Kansas, United States |
2282 | Completed | A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19 | COVID-19 | Drug: Ciclesonide Metered Dose Inhaler [Alvesco] | Phase 2 | Korea University Guro Hospital | OTHER | 68 | All | 19 Years ~ 80 Years | Korea University Guro Hospital, Seoul, Korea, Republic of |
2281 | Terminated | A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 | SARS-CoV-2 Infection | Drug: GC4419 Drug: Placebo |
Phase 2 | Galera Therapeutics, Inc. | INDUSTRY | 17 | All | 18 Years | University of Iowa, Iowa City, Iowa, United States Saint Louis University, Saint Louis, Missouri, United States Mercy Research, Saint Louis, Missouri, United States |
2280 | Not yet recruiting | A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients | SARS-CoV2 Infection | Drug: Recombinant cytokine gene derived protein injection | Phase 3 | Beijing 302 Hospital | OTHER | 300 | All | 18 Years ~ 65 Years | |
2279 | Recruiting | A Trial of NT-I7 in COVID-19 (SPESELPIS) | COVID-19 | Drug: Double-Blind NT-I7 Drug: Double-Blind Placebo |
Phase 1 | NeoImmuneTech, National Institute of Allergy and Infectious Diseases (NIAID), University of Nebraska | INDUSTRY | 30 | All | 19 Years ~ 75 Years | Nih/Niaid, Bethesda, Maryland, United States University of Nebraska Medical Center, Omaha, Nebraska, United States |
2278 | Suspended | A Trial of Remdesivir in Adults With Mild and Moderate COVID-19 | SARS-CoV-2 | Drug: Remdesivir Drug: Remdesivir placebo |
Phase 3 | Capital Medical University, Chinese Academy of Medical Sciences | OTHER | 308 | All | 18 Years | Jin Yin-tan hospital, Wuhan, Hubei, China |